Department of Ophthalmology & Optometry, Medical University Vienna, Vienna, Austria.
Am J Ophthalmol. 2010 May;149(5):777-84. doi: 10.1016/j.ajo.2009.12.010. Epub 2010 Feb 11.
To compare the anti-inflammatory efficacy and subjective tolerability of preservative-free and preserved diclofenac 0.1% and preserved ketorolac 0.5% eye drops for prophylaxis and management of inflammation after cataract surgery.
Prospective, randomized, investigator-masked, parallel-group, comparative clinical trial.
One hundred two patients who underwent small-incision phacoemulsification cataract surgery in an institutional setting were assigned randomly to receive preservative-free diclofenac sodium 0.1% (Voltaren ophtha SDU; Novartis Pharma), preserved diclofenac sodium 0.1% (Voltaren ophtha; Novartis Pharma), or preserved ketorolac tromethamine 0.5% (Acular; Pharm Allergan) eyedrops 4 times daily for 4 weeks after surgery. During the 1-month follow-up, anterior chamber flare and mean foveal thickness were evaluated for objective comparison of the anti-inflammatory effect. Ocular tolerability was assessed by observer-based grading of conjunctival hyperemia and ocular discomfort, as well as obtaining subjective ratings of ocular tolerability on a visual analog scale. Distance and near visual acuity and intraocular pressure served as safety measures.
All 3 formulations demonstrated equal anti-inflammatory efficacy as measured by reduction of anterior chamber flare after surgery and prevention of postoperative macular edema. Patients treated with preservative-free diclofenac eyedrops reported significantly better subjective tolerability values (P = .001), were classified as having less ocular discomfort (P < .001), and experienced earlier reduction of postoperative conjunctival hyperemia (P = .029).
Anti-inflammatory efficacy was comparable for all 3 agents. However, preservative-free diclofenac 0.1% eyedrops exhibited a significantly better postoperative subjective and objective tolerability when compared with preserved eyedrops containing ketorolac or diclofenac.
比较白内障术后炎症预防和治疗中使用的无防腐剂和含防腐剂的双氯芬酸钠 0.1%及酮咯酸氨丁三醇 0.5%滴眼液的抗炎疗效和主观耐受性。
前瞻性、随机、研究者设盲、平行组、对照临床试验。
102 例在机构环境下接受小切口超声乳化白内障手术的患者被随机分为 4 组,分别接受无防腐剂双氯芬酸钠 0.1%(Voltaren ophtha SDU;诺华制药)、含防腐剂双氯芬酸钠 0.1%(Voltaren ophtha;诺华制药)或含防腐剂酮咯酸氨丁三醇 0.5%(Acular;爱尔康制药)滴眼剂,每天 4 次,持续 4 周。在 1 个月的随访期间,通过评估前房闪辉和平均中心凹视网膜厚度来比较抗炎效果。通过观察者评估结膜充血和眼部不适的分级以及通过视觉模拟评分评估患者对眼部耐受性的主观评分来评估眼部耐受性。远、近视力和眼压作为安全性指标。
3 种制剂在减少术后前房闪辉和预防术后黄斑水肿方面均表现出相同的抗炎疗效。与使用含防腐剂滴眼剂的患者相比,使用无防腐剂双氯芬酸钠滴眼剂的患者报告的主观耐受性更好(P=.001),眼部不适程度较轻(P <.001),术后结膜充血减轻更早(P=.029)。
3 种药物的抗炎疗效相当。然而,与含有酮咯酸或双氯芬酸钠的防腐剂滴眼剂相比,无防腐剂双氯芬酸钠 0.1%滴眼剂在术后的主观和客观耐受性方面表现出更好的效果。